Literature DB >> 8496592

Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.

A Yoshimura1, H Shiku, E Nakayama.   

Abstract

FBL-3N is an MHC class II Ag+ variant line that was obtained spontaneously during maintenance of Friend virus-induced leukemia FBL-3 in an athymic C57BL/6 (B6) mouse. Inocula of FBL-3N, but not the parental FBL-3 tumor, regressed after initial growth in CD8-depleted, syngeneic B6 mice. The cellular mechanisms by which FBL-3N was rejected in these mice were investigated in this study. We demonstrated that CTL with both CD4+ and CD4-CD8-TCR-alpha beta phenotypes were generated in mixed lymphocyte tumor cell culture spleen cells obtained from CD8-depleted B6 mice that had rejected FBL-3N by in vitro stimulation with mitomycin C-treated FBL-3N. After adoptive transfer of these CTL that were generated in vitro into athymic B6 mice, challenge with the FBL-3N tumor resulted in tumor regression after its initial growth. Thus, CD4+ and CD4-CD8-TCR-alpha beta CTL mediated rejection of the FBL-3N tumor in CD8-depleted B6 mice. Furthermore, the findings that depletion of B6 mice of CD4+ cells in addition to CD8+ cells abrogated the rejection of FBL-3N and generation of CTL in mixed lymphocyte tumor cell culture spleen cells suggest that CD4+ cells were required not only as a source of CD4+ CTL, but also as helper cells for generation of CD4-CD8-TCR-alpha beta CTL. Tumor Ag recognition of CD4-CD8-TCR-alpha beta CTL was restricted to Db, like that of classical CD8+ CTL, but the restriction appeared to be less obligatory than that of CD8+ CTL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496592

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Role of natural killer cells in resistance against friend retrovirus-induced leukemia.

Authors:  N Iwanami; A Niwa; Y Yasutomi; N Tabata; M Miyazawa
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  A synergistic antitumor effect of interleukin-2 addition with CD80 immunogene therapy for peritoneal metastasis of gastric carcinoma.

Authors:  Kinshi Kosaka; Masakazu Yashiro; Yoji Sakate; Kosei Hirakawa
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

3.  Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells.

Authors:  Philip J Norris; Howell F Moffett; Otto O Yang; Daniel E Kaufmann; Margaret J Clark; Marylyn M Addo; Eric S Rosenberg
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

4.  Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells.

Authors:  Ilseyar Akhmetzyanova; Gennadiy Zelinskyy; Simone Schimmer; Sven Brandau; Petra Altenhoff; Tim Sparwasser; Ulf Dittmer
Journal:  Cancer Immunol Immunother       Date:  2012-08-14       Impact factor: 6.968

Review 5.  Regulation of tumor growth by IFN-gamma in cancer immunotherapy.

Authors:  G L Beatty; Y Paterson
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

6.  Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.

Authors:  F Ossendorp; E Mengedé; M Camps; R Filius; C J Melief
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

7.  Reconstitution of anti-tumor effects of lentinan in nude mice: roles of delayed-type hypersensitivity reaction triggered by CD4-positive T cell clone in the infiltration of effector cells into tumor.

Authors:  M Suzuki; M Iwashiro; F Takatsuki; K Kuribayashi; J Hamuro
Journal:  Jpn J Cancer Res       Date:  1994-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.